We checked gene expression signatures from biomarker analyses of the Javelin101 and IMmotion150 trials and the tLHP signature which was recently developed as an ICI biomarker for ccRCC, and PD-L1 (by CD274 expression) [19–21]. Here, CD274 is linked to nonpapillary renal cell carcinoma.